论文部分内容阅读
目的:观察米力农治疗婴幼儿重症肺炎合并心力衰竭的疗效及安全性。方法:重症肺炎合并心力衰竭患儿48例,随机分为治疗组与对照组各24例,在常规治疗基础上,治疗组予米力农治疗,对照组予多巴胺治疗。结果:治疗组与对照组有效率分别为95.8%和66.7%,两组间差异有统计学意义(2χ=4.92,P<0.05);治疗组与对照组治疗后心功能指标差异有统计学意义(P<0.05)。两组均未出现不良反应。结论:米力农治疗婴幼儿重症肺炎合并心力衰竭是安全有效的。
Objective: To observe the efficacy and safety of Milrinone in the treatment of infantile severe pneumonia complicated with heart failure. Methods: Forty-eight children with severe pneumonia complicated with heart failure were randomly divided into treatment group and control group with 24 cases each. On the basis of routine treatment, the treatment group was treated with milrinone and the control group with dopamine treatment. Results: The effective rates of the treatment group and the control group were 95.8% and 66.7%, respectively, with significant difference between the two groups (2χ = 4.92, P <0.05); the difference of the cardiac function indexes between the treatment group and the control group after treatment was statistically significant (P <0.05). No adverse reactions occurred in both groups. Conclusion: Milrinone treatment of infantile severe pneumonia complicated with heart failure is safe and effective.